TrialNature communications2023

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Othman Al-Sawaf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.